학술논문
Discovery of a drug candidate for GLIS3-associated diabetes
Document Type
article
Author
Source
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Subject
Language
English
ISSN
2041-1723
Abstract
GLIS3 mutations are associated with type 1, type 2, and neonatal diabetes. Here, the authors generate mono-hormonal glucose-responding pancreatic β-like cells in vitro and through a screen identify a drug that rescues pancreatic β-like cell death in GLIS3 mutants by inhibiting the abnormally activated TGFβ pathway.